AstraZeneca bolsters respiratory portfolio with new asthma candidate
This article was originally published in Scrip
Executive Summary
AstraZeneca has signed a global license agreement with UK-based Synairgen for the latter's inhaled form of interferon beta (IFN-beta), which is being developed to treat respiratory tract viral infections in patients with severe asthma.